{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:27:24Z","timestamp":1787110044708,"version":"build-2736575974"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,18]]},"DOI":"10.7759\/cureus.114762","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:48:01Z","timestamp":1787107681000},"source":"Crossref","is-referenced-by-count":0,"title":["An Early Single-Center Case Series Experience With a Recently Introduced Formulation of Inhaled Treprostinil (Yutrepia)"],"prefix":"10.7759","author":[{"given":"Christopher R","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew I","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekhar","family":"Ghamande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12119","article-title":"INSPIRE: safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)","volume":"12","author":"Hill NS","year":"2022","unstructured":"Hill NS, Feldman JP, Sahay S, et al.. INSPIRE: safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH). Pulm Circ. 2022, 12:e12119. 10.1002\/pul2.12119","journal-title":"Pulm Circ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020971509","article-title":"Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil","volume":"10","author":"Roscigno R","year":"2020","unstructured":"Roscigno R, Vaughn T, Anderson S, Wargin W, Hunt T, Hill NS. Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil. Pulm Circ. 2020, 10:2045894020971509. 10.1177\/2045894020971509","journal-title":"Pulm Circ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03129-3","article-title":"Pulmonary hypertension associated with interstitial lung disease (PH-ILD): back to the future","volume":"42","author":"Fiorent\u00f9 G","year":"2025","unstructured":"Fiorent\u00f9 G, Bernardinello N, Giulianelli G, Cocconcelli E, Balestro E, Spagnolo P. Pulmonary hypertension associated with interstitial lung disease (PH-ILD): back to the future. Adv Ther. 2025, 42:1627-41. 10.1007\/s12325-025-03129-3","journal-title":"Adv Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman A","year":"2021","unstructured":"Waxman A, Restrepo-Jaramillo R, Thenappan T, et al.. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021, 384:325-34. 10.1056\/NEJMoa2008470","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","volume":"64","author":"Kovacs G","year":"2024","unstructured":"Kovacs G, Bartolome S, Denton CP, et al.. Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J. 2024, 64:2401324. 10.1183\/13993003.01324-2024","journal-title":"Eur Respir J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert M","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al.. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022, 43:3618-731. 10.1093\/eurheartj\/ehac237","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106806","article-title":"Practical considerations in the management of inhaled prostacyclin therapy for pulmonary hypertension associated with interstitial lung disease (WHO group 3)","volume":"196","author":"Lee C","year":"2022","unstructured":"Lee C, Hamlyn J, Porcelli J, Schmit A. Practical considerations in the management of inhaled prostacyclin therapy for pulmonary hypertension associated with interstitial lung disease (WHO group 3). Respir Med. 2022, 196:106806. 10.1016\/j.rmed.2022.106806","journal-title":"Respir Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S19281","article-title":"Inhaled treprostinil: a therapeutic review","volume":"6","author":"Channick RN","year":"2012","unstructured":"Channick RN, Voswinckel R, Rubin LJ. Inhaled treprostinil: a therapeutic review. Drug Des Devel Ther. 2012, 6:19-28. 10.2147\/DDDT.S19281","journal-title":"Drug Des Devel Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"46","author":"Gali\u00e8 N","year":"2015","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, et al.. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015, 46:903-75. 10.1183\/13993003.01032-2015","journal-title":"Eur Respir J"},{"key":"ref10","article-title":"A Comprehensive Comparison of the Wald, Wilson, and adjusted Wilson Confidence Intervals for Proportions","author":"Kahouadji N","year":"2025","unstructured":"Kahouadji N. A Comprehensive Comparison of the Wald, Wilson, and adjusted Wilson Confidence Intervals for Proportions. 2025."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1086\/688059","article-title":"An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension","volume":"6","author":"Zamanian RT","year":"2016","unstructured":"Zamanian RT, Levine DJ, Bourge RC, et al.. An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension. Pulm Circ. 2016, 6:329-37. 10.1086\/688059","journal-title":"Pulm Circ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhlto.2024.100131","article-title":"Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil","volume":"6","author":"Swaminathan AC","year":"2024","unstructured":"Swaminathan AC, Meservey A, Parish A, et al.. Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil. JHLT Open. 2024, 6:100131. 10.1016\/j.jhlto.2024.100131","journal-title":"JHLT Open"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029024","article-title":"Revised definition of pulmonary hypertension and approach to management: a clinical primer","volume":"12","author":"Maron BA","year":"2023","unstructured":"Maron BA. Revised definition of pulmonary hypertension and approach to management: a clinical primer. J Am Heart Assoc. 2023, 12:e029024. 10.1161\/JAHA.122.029024","journal-title":"J Am Heart Assoc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/510990-an-early-single-center-case-series-experience-with-a-recently-introduced-formulation-of-inhaled-treprostinil-yutrepia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:48:02Z","timestamp":1787107682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/510990-an-early-single-center-case-series-experience-with-a-recently-introduced-formulation-of-inhaled-treprostinil-yutrepia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.114762","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}